BeiGene wants to ensure access to medicines for all patients and puts patients first in the fight against cancer. We foster strong collaborations that extend to the furtherest reaches of the globe. Learn more about the BeiGene story.
Video
BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its state-of-the-art biologics facility in Guangzhou, China.
Video
A global biotechnology innovator focused on improving treatment outcomes and patient access
Lettura
La nostra mission: I pazienti prima di tutto grazie alla scienza e all’accesso alle cure
Lettura
A warm welcome from BeiGene CEO John V. Oyler on the Company’s virtual congress site.
Video
